Company intelligence / Profile preview

Radiomer Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Radiomer’s lead programs are advancing assets against both established and novel cancer targets. The company expects its first human data from a Phase 0 imaging/dosimetry trial in early/mid–2025. No published efficacy results yet as the company remains pre-commercial and at the start of clinical development.

Therapeutic areas: Oncology
Modalities: Targeted radiopharmaceuticals / radioligand therapies (RLTs)Raptamers™ (peptide–oligonucleotide hybrids)
Industry: Biotech

Beyond the preview

Go deeper on Radiomer Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radiomer Therapeutics.

Explore the full profile